Loading...
Generating destination analysis
Catalyst Play
Featured in “Three Gene-Editing Stocks to Own Before Biotech's Fall 2026 Catalyst Wave”
Fall '26 Readouts
Beam Therapeutics pioneered base editing — rewriting DNA without cutting it, with far fewer off-target effects. With hematology front and center at ASH and its lead programs advancing, Beam is the highest-leverage way to own the next generation of genetic medicine.
The catalyst: The back half of 2026 is one of the most catalyst-dense stretches biotech has seen in years. The ESMO oncology congress and the ASH hematology meeting both land in the autumn, and the FDA's decision calendar is stacked — including a closely watched November 14 PDUFA date for ivonescimab in lung cancer. Clusters like this drive sector-wide risk-on, and capital flows first to the platforms with the deepest pipelines and clearest readouts. These three sit at the center of genetic medicine.
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$3B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About Beam Therapeutics
Beam Therapeutics is a small-cap biotech company listed on the NASDAQ, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. Base editing platform with differentiated gene-editing pipeline. With a $3B market capitalization and no current profitability, Beam Therapeutics has delivered revenue headwinds with revenue moving 0% over the past year.
Expert Coverage
Unlock Full BEAM Analysis
Expert analysis and coverage for Beam Therapeutics
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-06-28
More in Biotech & Genomics
DXCM
DexCom Inc.
90
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%RXRX
Recursion Pharmaceuticals
88
True North
Pure Play
AI-driven drug discovery platform using machine learning to decode biology at scale.
NASDAQ
MCap $4BRev +55%CRSP
CRISPR Therapeutics
86
True North
Pure Play
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
NASDAQ
MCap $5BRev +350%